The findings have led the discussions on the possible design of a clinical study. ‘These observations suggest a strategy for testing the efficacy of dasatinib in breast cancer patients who are positive for alpha – v beta – 3 receptor.’Said Barbara Parker, medical director of oncology services at Moores UCSD Cancer Center.
Of the receptor,ture identifies potential response to therapyA molecular signature, the bill for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma helps also predict the likelihood of successful treatment with a particular anti-cancer medicament. The finding to a to a resistant personalized approach for treating a variety of solid tumors that are currently against therapies will be released on 6 in the online edition of Nature Medicine will advance.An Associate Professor in the Division of Epidemiology and Public Health at Yale School of Medicine Yale team analyzed the genetic and environmental risk factors for the development of of DCIS. She genetically tested three hundred and sixty-nine women with DCIS on changes in in the BRCA1 and BRCA2. We have found 8 %age disease associated disease-associated mutations in BRCA1, whereas 2, high risk had such mutations are into BRC A2, said Claus. These figures are similar to that reports for women with advanced breast cancer. .. The inherited breasts / BRCA1 and BRCA2 genes BRCA1 and BRCA2, associated with an increased risk of breasts and / or ovarian cancer. The results are set part of a five -year study of of a common form in early breast cancer as the ductal carcinoma in situ .
The NIH funded the study.Other authors have include Darryl Carter, by EPH, yards Matloff, Cancer Genetic Counseling Shared Resource of the Yale Cancer Center and Stacey Petruzella which EPH. Citation: JAMA, February 2005.Contact: Karen N.